Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions

Int J Biol Sci. 2021 Jun 26;17(10):2666-2682. doi: 10.7150/ijbs.59117. eCollection 2021.

Abstract

Pancreatic cancer is a malignant tumor of the digestive system with a very high mortality rate. While gemcitabine-based chemotherapy is the predominant treatment for terminal pancreatic cancer, its therapeutic effect is not satisfactory. Recently, many studies have found that microorganisms not only play a consequential role in the occurrence and progression of pancreatic cancer but also modulate the effect of chemotherapy to some extent. Moreover, microorganisms may become an important biomarker for predicting pancreatic carcinogenesis and detecting the prognosis of pancreatic cancer. However, the existing experimental literature is not sufficient or convincing. Therefore, further exploration and experiments are imperative to understanding the mechanism underlying the interaction between microorganisms and pancreatic cancer. In this review, we primarily summarize and discuss the influences of oncolytic viruses and bacteria on pancreatic cancer chemotherapy because these are the two types of microorganisms that are most often studied. We focus on some potential methods specific to these two types of microorganisms that can be used to improve the efficacy of chemotherapy in pancreatic cancer therapy.

Keywords: Bacteria; Chemotherapy; Mycoplasma; Oncolytic viruses; Pancreatic cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / pharmacology*
  • Bacteria*
  • Carcinogenesis
  • Combined Modality Therapy
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / pharmacology
  • Gemcitabine
  • Humans
  • Oncolytic Viruses*
  • Pancreatic Neoplasms / therapy*

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine